Summary:
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of JNJ-27018966 compared with placebo in the treatment of patients with irritable bowel syndrome with diarrhea (IBS-d).
Qualified Participants Must:
• Have a diagnosis of IBS by Rome III criteria with a subtype of diarrhea
•
Have an average daily pain score of ≥3.0 on a 0- to 10-point scale over the past week
•
Have a weekly mean stool consistency score (BSS) of ≥5.5 over the past week
•
If female, be postmenopausal, defined as amenorrhea for at least 2 years, at pre-screening
•
If female, be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy)
•
If female, be abstinent, or if sexually active, be practicing an effective method of birth control
Qualified Participants May Receive:
Study related care, diagnostic tests, and study medication at no cost. Payment for time and travel to the study center may be provided.